Microcap Ledger Cocrystal Pharma, Inc. $COCP
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Bothell, WA
- Fiscal year end
- December 31
- Shares outstanding
- 19,263,200 [10-Q 2026-08-13]
What the company doesAI summary of filing
Cocrystal Pharma is a clinical-stage biotechnology company developing small molecule antiviral drugs targeting RNA viruses including influenza, norovirus, coronavirus (including SARS-CoV-2), and hepatitis C virus. The company uses a proprietary structure-based drug discovery platform incorporating computational chemistry, medicinal chemistry, and X-ray crystallography to design direct-acting antiviral compounds. The company has not yet received regulatory approval for or commercialized any product candidates. It currently employs 10 full-time employees and engages clinical research organizations and consultants to support its research and development activities. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $330.0K | −$5.46M | −$4.86M | $2.17M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$8.83M | −$8.19M | $7.03M | [DEF 14A 2026-05-27] |
| FY ended Dec 2024 | — | −$17.50M | −$16.48M | $9.86M | [DEF 14A 2026-05-27] |
- Quarterly cash burn
- −$2.43M
- Cash runway Estimate
- ~2.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 10,173,790 | [10-Q 2024-11-13] |
| 2025-03-31 | 10,173,790 | [10-K 2025-03-31] |
| 2025-05-15 | 10,173,790 | [10-Q 2025-05-15] |
| 2025-08-12 | 10,258,866 | [10-Q 2025-08-14] |
| 2025-11-14 | 13,784,065 | [10-Q 2025-11-14] |
| 2026-03-24 | 13,785,759 | [10-K 2026-03-31] |
| 2026-05-15 | 13,787,453 | [10-Q 2026-05-15] |
| 2026-08-13 | 19,263,200 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-04-23; declared effective 2026-05-01 [S-3 2026-04-23]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-05 | Frost Phillip Md Et Al | buy | 10,000 | $0.98 | [4 2026-08-06] |
| 2026-08-03 | Frost Phillip Md Et Al | buy | 75,000 | $0.94 | [4 2026-08-05] |
| 2026-02-24 | Frost Phillip Md Et Al | buy | 20,000 | $1.00 | [4 2026-02-25] |
| 2026-02-06 | Frost Phillip Md Et Al | buy | 50,000 | $0.95 | [4 2026-02-09] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-09 | 8-K | Regulation FD disclosure |
| 2026-08-18 | 8-K | Director or officer change |
| 2026-08-17 | 8-K | Regulation FD disclosure |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-07 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-03 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-07-17 | 8-K | Shareholder vote results |
| 2026-06-09 | 8-K | Director or officer change |
| 2026-06-03 | 8-K | Regulation FD disclosure |
| 2026-05-27 | DEF 14A | Proxy statement |
| 2026-05-26 | 8-K | Regulation FD disclosure |
Alerts for $COCP
Email me when Cocrystal Pharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.